A 2-year follow-up of the randomized, placebo-controlled BANDIT trial shows that stopping baricitinib leads to a loss of therapeutic benefit, supporting its evaluation in earlier stages of type 1 diabetes to determine whether it can prevent or delay clinical onset. In 2023, researchers in Australia launched the pioneering BANDIT (Baricitinib in New Onset Type 1 […]
Click the Source link for more details
Hot this week
Popular Categories
Free News - Where voices unite, stories flourish, and community thrives through open dialogue and meaningful connections.
Get important news delivered directly to your inbox and stay connected!
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
These cookies are needed for adding comments on this website.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com (opens in a new window)
